[Clinical study of the lipotropic activity of the preparation Fosfolip].
A randomized and double blind experiment has been made over 50 patients and 25 checks, by giving a dosage of 3 Fosfolip (calcium salt of phosphorylcholine chlorid with pantethine) capsules a day. The analysis results has been reported in the work. In none case the product had secondary no desired effects; while therapeutical possibilities have been resulted in hepatosis, dyslipidosis and as energetic tonic in atherosclerotic subjects.
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy; D002794:Choline / Q000031:analogs & derivatives*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D008055:Lipids / Q000097:blood; D008107:Liver Diseases / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010204:Pantetheine / Q000031:analogs & derivatives / Q000627:therapeutic use*; D010767:Phosphorylcholine / Q000627:therapeutic use*; D013438:Sulfhydryl Compounds / Q000627:therapeutic use*
D004338:Drug Combinations; D008055:Lipids; D013438:Sulfhydryl Compounds; D010767:Phosphorylcholine; D010204:Pantetheine; C005425:pantethine; C037751:fosfolip; D002794:Choline
Studio clinico sull'attività lipotropica del preparato "Fosfolip".